Live Breaking News & Updates on ஆலிவர் டேகிளெர்க்க்

Stay updated with breaking news from ஆலிவர் டேகிளெர்க்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead
Hyloris Pharmaceuticals SAAugust 4, 2021 GMT
 On target to grow the broad product pipeline with at least 3 additional programmes before end 2021
Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV
Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end
€53.47 million in cash and cash equivalents to execute ambitious growth strategy
Conference call and webcast today at 3pm CEST/9am EST (details below)
Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month p ....

United States , United Kingdom , Marieke Vermeersch , Stijn Van Rompay , Miconazole Domiphen , Olivier Declercq , Chris Buyse , Alter Pharma Group For Maxigesic , Alter Pharma Group , International Standard On Review Engagements , Hyloris Pharmaceuticals , Company Group Structure , Hyloris Pharmaceuticals Sa Euronext Brussels , Corporate Communications , Pharma Bavaria International , Hikma Pharmaceuticals , Euronext Brussels , Van Rompay , Chief Executive Officer , South America , Latin America , Purna Female Healthcare , Miconazole Domiphen Bromide , Tranexamic Acid , Fusidic Acid , Alter Pharma ,

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results


Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results
On track to fuel the pipeline with =4 new product candidates in 2021
Strong cash position of €64 million year-end to execute ambitious growth plan
14 commercial products expected by 2024
Conference call and
Liège, Belgium - 9 March 2021 -
Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 December 2020, recent achievements, and an outlook for 2021.
Stijn Van Rompay, Chief Executive Officer of Hyloris, commented:
I am extremely proud of the significant progress we have made across all areas of our business, which has set a strong foundation to execute our ambitious growth plan. We are committed to changing the lives of patients by applying our kno ....

United States , Hong Kong , United Kingdom , Czech Republic , Region Flamande , United Arab Emirates , Abuz Aby , New Zealand , Amber Fennell , Van Rompay , Kensington Pharma , Biocapital Europe , Olivier Declercq , Chris Welsh , Marc Foidart , Marieke Vermeersch , Carolyn Myers , Stijn Van Rompay , Ted Maloney , Chris Buyse , Lucy Featherstone , National Marketing Authorizations , University Of Antwerp Belgium , European Union , Kempen Life Sciences Conference , Hyloris Pharmaceuticals ,